Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502800 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of ARQ 761 in Advanced Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 1
- Study location
NCT01502800: Completed Phase 1 study of Solid Tumors, sponsored by University of Texas Southwestern Medical Center.
NCT01502800 is a Phase 1 study of Solid Tumors that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 91 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01502800, a Phase 1 study of Solid Tumors, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 761 administered intravenously. Secondary Objectives: To determine the pharmacokinetic profile of ARQ 761 To assess the preliminary anti-tumor activity of aRQ 761
Primary Outcome
To determine the recommended Phase 2 dose (RP2D) of ARQ 761 administered intravenously.
Conditions Studied
Interventions
- DRUG ARQ 761
- DRUG ARQ 761 Weekly Administration
- DRUG Bi-Weekly Administration of ARQ 761
- DRUG Two Consecutive Weeks Administration of ARQ 761 with one week of rest
Study Locations (1)
Texas
- UT Southwestern Medical Center - Simmons Cancer Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2011-12-29 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
What the finished NCT01502800 record still lists
NCT01502800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which ARQ 761 is the first listed.
NCT01502800 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01502800 about?
NCT01502800 is a clinical study titled "Clinical Trial of ARQ 761 in Advanced Solid Tumors". Primary Objective: To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 761 administered intravenously. Secondary Objectives: To determine the pharmacokinetic profile of ARQ 761 To assess the preliminary anti-tumor activity of aRQ 761
What is the current status of trial NCT01502800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2011-12-29. Estimated completion is 2019-03.
What conditions does trial NCT01502800 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT01502800?
The interventions under investigation include: ARQ 761 (DRUG), ARQ 761 Weekly Administration (DRUG), Bi-Weekly Administration of ARQ 761 (DRUG), Two Consecutive Weeks Administration of ARQ 761 with one week of rest (DRUG).
Who is sponsoring clinical trial NCT01502800?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01502800 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01502800's enrollment target sits among peer trials
91 55th of 125 higher than 71 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI